- Home
- SACH vs XGN Comparison
SACH vs XGN Comparison
Compare SACH & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SACH
- XGN
- Stock Information
- Founded
- SACH 2010
- XGN 2002
- Country
- SACH United States
- XGN United States
- Employees
- SACH N/A
- XGN N/A
- Industry
- SACH Real Estate Investment Trusts
- XGN Medical Specialities
- Sector
- SACH Real Estate
- XGN Health Care
- Exchange
- SACH Nasdaq
- XGN Nasdaq
- Market Cap
- SACH 61.5M
- XGN 72.3M
- IPO Year
- SACH 2017
- XGN 2019
- Fundamental
- Price
- SACH $1.19
- XGN $5.02
- Analyst Decision
- SACH Buy
- XGN Buy
- Analyst Count
- SACH 2
- XGN 1
- Target Price
- SACH $2.25
- XGN $7.00
- AVG Volume (30 Days)
- SACH 512.1K
- XGN 162.5K
- Earning Date
- SACH 11-14-2024
- XGN 11-12-2024
- Dividend Yield
- SACH 19.92%
- XGN N/A
- EPS Growth
- SACH N/A
- XGN N/A
- EPS
- SACH N/A
- XGN N/A
- Revenue
- SACH $10,951,064.00
- XGN $55,751,000.00
- Revenue This Year
- SACH N/A
- XGN $6.74
- Revenue Next Year
- SACH N/A
- XGN $17.32
- P/E Ratio
- SACH N/A
- XGN N/A
- Revenue Growth
- SACH N/A
- XGN 8.00
- 52 Week Low
- SACH $1.15
- XGN $1.30
- 52 Week High
- SACH $4.64
- XGN $6.22
- Technical
- Relative Strength Index (RSI)
- SACH 25.83
- XGN 56.40
- Support Level
- SACH $1.15
- XGN $4.71
- Resistance Level
- SACH $1.48
- XGN $5.41
- Average True Range (ATR)
- SACH 0.07
- XGN 0.56
- MACD
- SACH 0.01
- XGN -0.07
- Stochastic Oscillator
- SACH 11.89
- XGN 39.70
About SACH Sachem Capital Corp.
Sachem Capital Corp is a United States-based real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns majority of its revenue through Interest income from loans.
About XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.